Veraxa Biotech (VRXA) Q4 2025 earnings summary

Executive summary

• Oncology-focused biotech with an AML clinical program and antibody-drug conjugate (ADC) and T-cell engager platforms; FY2025 revenue was CHF 23,426 and net loss widened to CHF 66.6m from CHF 28.1m.

• Business combination closed June 10, 2026; subsequent financing includes a $27.5m senior secured note and access to up to $50m through Lincoln Park.

Financial highlights

• FY2025 revenue CHF 23,426 versus nil in 2024; gross profit CHF 15,461 after CHF 7,965 cost of goods sold.

• Operating loss widened 129% YoY to CHF 66.2m; net loss rose 137% to CHF 66.6m, including CHF 0.8m fair-value loss on contingent liabilities.

• G&A rose to CHF 46.9m, primarily reflecting higher share-based compensation; R&D increased 63% to CHF 10.3m and sales and marketing increased 91% to CHF 6.9m.

• FY2025 basic and diluted loss per share was CHF 4.60 versus CHF 2.00 in 2024; comprehensive loss was CHF 66.7m versus CHF 28.4m.

• Operating cash outflow was CHF 9.9m, investing outflow CHF 0.4m and financing inflow CHF 6.6m; year-end cash was CHF 1.6m.

Outlook and guidance

• Management assessed liquidity including HTC proceeds and access to Lincoln Park capital, concluding planned operations and obligations can be funded for at least 12 months from the financial statements’ issuance date.

• Future capital needs depend on R&D and sales and marketing spend; additional equity or debt financing may be needed, with no assurance of acceptable terms or availability.

• Earnout eligibility spans the three fiscal years after closing, linked to share-price VWAP thresholds of $11.00, $12.50 and $14.00 by year-end 2026, 2027 and 2028, respectively.